Wipe-Out or Snuff-Out Phenomenon

Wipe-out, also called snuff-out, is a sudden, severe, and usually irreversible loss of the remaining central vision that can happen soon after glaucoma surgery (most often after filtering procedures like trabeculectomy). It is reported mainly in eyes with very advanced glaucoma, where the optic nerve and central macular visual field are already critically damaged. Importantly, wipe-out is a diagnosis of exclusion—it is said to occur when no other clear cause can fully explain the sharp vision loss (for example, not a big pressure spike, not obvious hypotony maculopathy, not a stroke of the optic nerve, not a surgical complication you can see). Although feared, it appears to be uncommon. EyeWikiPMCLippincott JournalsGlaucoma TodayJAMA Network

Wipe-out (also called snuff-out) is a sudden, painless, and permanent loss of central vision that can happen right after glaucoma surgery, most often in an eye that already has very advanced glaucoma and a severely damaged optic nerve. Doctors use the word “wipe-out” when a patient loses the remaining “island” of central sight without another obvious cause (no retinal detachment, no artery blockage, etc.). It is rare, but it is a feared complication because the sight that is lost usually does not come back. EyeWikiPMC+

Typically “I can’t see like before” immediately or within days after surgery, without eye pain or redness. Clinicians worry most when pre-op testing shows split fixation or central field loss—meaning the last islands of vision are fragile. EyeWiki  Reported rates vary by study and definition—from 0% up to ~7% after trabeculectomy—again stressing how controversial and uncommon this entity is. Glaucoma TodayAmerican Academy of Ophthalmology

Why it may happen

Even though wipe-out is defined as “unexplained,” several likely contributors are discussed in the literature:

• Critically thin optic nerve reserve: in end-stage glaucoma, even small blood-flow dips or pressure swings can tip remaining nerve fibers into failure. JAMA Network

• Intraocular pressure (IOP) changes: a very fast drop in IOP (right after filtering surgery) may alter perfusion across the lamina cribrosa and retina; conversely IOP spikes can also harm the fragile nerve. Ajo

• Hypotony and its effects: very low IOP (hypotony) can cause choroidal effusions, macular folds, cystoid macular edema, and optic disc edema, each capable of tanking best-corrected vision. Even when these are visible (and thus not “true” wipe-out), they are frequent culprits of early vision loss after surgery. PMCMedscapeAmerican Academy of Ophthalmology

• Ischemic optic neuropathy or vascular dysregulation: rare postoperative optic nerve ischemia—sometimes linked to nocturnal systemic hypotension or vascular risk—can mimic or be labeled as wipe-out. American Academy of Ophthalmology

• Other named causes that must be ruled out: lens changes, persistent macular edema, suprachoroidal hemorrhage, chronic hypotony remodeling, or coexisting optic nerve disease (rarely, e.g., optic nerve sheath meningioma) can all reduce vision after filtration surgery. ResearchGateScienceDirectKlinika Oczna

In advanced glaucoma the optic nerve is fragile. Even small changes in eye pressure or blood flow around the nerve can be “the last straw” for the few remaining nerve fibers. Several mechanisms are suspected: brief very low pressure after surgery (hypotony) with fluid collecting behind the retina (choroidal effusions), pressure spikes, poor blood flow to the optic nerve, or ischemia–reperfusion injury in a nerve that was already on the edge. Not all experts agree on how often true wipe-out happens, but most agree it is rare and seen mainly in severe/end-stage glaucoma. MDPIGlaucoma Today

---

Types

There is no single “official” classification. Clinicians usually group cases by when it happens, which operation was done, and the likely mechanism. This framework is useful at the bedside.

1. By timing

   • Immediate (day 0–1): vision is poor as soon as the patch comes off. Often linked to marked hypotony or early choroidal effusion in a vulnerable nerve.

   • Early (first week): the patient notices central blur or a dark spot within days; may relate to pressure swings, early bleb over-filtration, or evolving effusions.

   • Late (weeks): much less typical for true wipe-out; look hard for another diagnosis (“pseudo–wipe-out”) like macular edema or vein occlusion.

2. By procedure

   • Trabeculectomy / filtering surgery: historically most reported. Incidence estimates in older series vary widely from ~0% to ~7% because definitions and patient selection differ. Glaucoma TodayAmerican Academy of Ophthalmology

   • Glaucoma drainage device (tube shunt): uncommon but reported (e.g., ~2–3% in some series). Risk increases when the pre-op field shows split fixation. PMC

   • Other glaucoma surgeries (deep sclerectomy, some MIGS): thought to be lower risk with modern techniques, but advanced-field eyes remain vulnerable. MDPI

   • Non-glaucoma surgery: very rare reports after cataract surgery, mostly in people with advanced glaucoma already. Health Research Authority

3. By suspected mechanism

   • Hypotony-driven (very low post-op IOP → choroidal effusion / reduced perfusion).

   • Pressure-spike–driven (IOP surge → stress on the last functioning fibers).

   • Hypoperfusion / vascular instability (systemic hypotension, vasospasm, nocturnal dips).

   • Anesthesia/peri-operative factors (e.g., tight retro/peribulbar injection in an eye with fragile optic nerve).

   • Pseudo–wipe-out (actually due to another occult cause that must be ruled out).

---

Causes

Below, “cause” means either a likely trigger/mechanism in a high-risk eye or a look-alike condition that can be mislabelled as wipe-out if not carefully excluded.

1. Advanced glaucoma with “split fixation.” The central 10° of the visual field is already broken; a tiny extra hit can erase central sight. Strongly linked to wipe-out risk. PubMedPMC

2. Immediate post-operative hypotony (very low IOP). Can collapse ocular perfusion and promote choroidal effusions in a vulnerable nerve. MDPI

3. Post-operative choroidal effusions. Fluid under the choroid reduces retinal/choroidal blood flow; often travels with hypotony. PubMed

4. Large IOP spikes. A sudden rise stresses sick ganglion cells and may close capillaries feeding the optic nerve head. Glaucoma Today

5. Ischemia–reperfusion injury. A brief period of low perfusion followed by re-perfusion may trigger apoptosis in already damaged cells. MDPI

6. Compromised optic nerve head perfusion (baseline). Long-standing poor circulation leaves no “reserve.” MDPI

7. Older age. Often travels with worse baseline fields and vascular lability. MDPI

8. Systemic hypotension (including nocturnal dips). Less blood reaches the nerve at critical moments. MDPI

9. Anemia/hypoxia around surgery. Low oxygen delivery makes vulnerable axons fail. (Clinical rule-out based on peri-op labs and history.)

10. Vasospastic tendency (e.g., migraine, Raynaud-type behavior). Transient vessel narrowing can tip perfusion below a threshold.

11. Peri-/retrobulbar anesthesia pressure. A tight injection may briefly elevate orbital pressure or reduce arterial inflow in rare cases. (Mechanistic concern described in case discussions.) Upjo

12. Over-filtration from the bleb early on. Too much outflow → hypotony → risk to perfusion.

13. Suprachoroidal hemorrhage. A true surgical complication that mimics wipe-out but is a distinct diagnosis needing urgent care. (Must be ruled out.)

14. Serous choroidal detachment. Another hypotony-related look-alike that degrades central vision until treated.

15. Macular edema / hypotony maculopathy. Causes central blur and distortion; can be mislabelled as wipe-out if OCT is not done.

16. Central retinal artery or vein occlusion. Catastrophic vascular events that must be excluded in every sudden vision loss case.

17. Ischemic optic neuropathy (non-arteritic or arteritic). Sudden central loss; check for scalp tenderness, jaw claudication, ESR/CRP in older adults to rule out giant cell arteritis.

18. Cystoid macular edema after cataract surgery. Commoner cause of central blur; distinguish on OCT/angiography.

19. Retinal detachment involving the macula. Obvious on dilated exam or B-scan if media is hazy.

20. Medication-related toxicity (rare). For example, acute IOP or perfusion changes related to systemic agents; uncommon but part of a broad differential.

Causes 1–8 capture intrinsic risk and pathophysiology of wipe-out in advanced glaucoma; 9–20 emphasize conditions to rule out so we don’t mislabel a fixable problem as wipe-out.

---

Symptoms

1. Sudden, painless drop in central vision right after surgery or when the patch comes off.

2. A central dark spot (central scotoma) or a missing patch exactly where you look.

3. Blurry reading vision that does not improve with blinking or pinhole.

4. Colors look washed out (dyschromatopsia) compared to the other eye.

5. Reduced contrast—grey on grey becomes hard to separate.

6. Faces are hard to recognize unless very close.

7. Trouble seeing fine print even with the best glasses.

8. Worse vision in dim light (low-contrast conditions).

9. More glare disability—lights scatter but don’t increase clarity.

10. Difficulty with fixation (keeping gaze on a small target).

11. Central “hole” on Amsler grid if the patient checks at home.

12. No pain, no redness typical for true wipe-out (pain suggests another problem). EyeWiki

13. No improvement with new glasses (refractive change does not explain it).

14. No obvious floaters or flashes (if present, think vitreoretinal disease).

15. Often one-sided (the operated eye), with the fellow eye serving as the comparison.

---

Diagnostic tests

(Grouped as Physical Exam, Manual tests, Lab & Pathology, Electrodiagnostic, Imaging. The goal is to confirm the pattern, measure the loss, and exclude other causes.)

A) Physical exam

1. Best-corrected visual acuity (BCVA). Measures the exact loss in letters/lines and tracks change over time; pinhole often does not fix wipe-out.

2. Intraocular pressure (IOP) measurement. Looks for hypotony or spikes that could explain the event and guides urgent management. EyeWiki

3. Pupil exam with RAPD check. A new relative afferent pupillary defect supports new optic-nerve-level damage.

4. Slit-lamp biomicroscopy. Assesses the bleb, anterior chamber depth, inflammation, and signs of over-filtration.

5. Dilated fundus examination. Looks for choroidal effusions, macular problems, or vascular occlusions; evaluates cup-to-disc ratio progression. EyeWiki

B) Manual tests

6. Confrontation visual fields. A quick bedside map to detect a new central or paracentral defect.

7. Amsler grid. Simple central field screening the patient can describe in clinic and at home.

8. Red desaturation / brightness comparison. Sensitive for fresh optic nerve dysfunction.

9. Swinging-flashlight test. Confirms strength and side of any RAPD.

C) Lab & pathological tests

10. Complete blood count (CBC). Screens for anemia that could worsen optic nerve perfusion.

11. ESR and CRP in older adults. Rules out giant cell arteritis if history suggests it (jaw pain, scalp tenderness) because arteritic ischemic neuropathy can mimic wipe-out.

12. Metabolic panel & glucose. Reviews systemic status and peri-operative risks (hypotension, dehydration).

13. Hypercoagulability / vasculitis work-up (selective). Only if history or exam points to vascular occlusive disease as a masquerader.

D) Electrodiagnostic tests

14. Visual evoked potential (VEP). Measures signal conduction from retina to brain; reduced amplitude/ increased latency supports optic nerve dysfunction when the fundus looks quiet.

15. Pattern electroretinogram (PERG) / photopic negative response. Assesses retinal ganglion cell function, often depressed in glaucoma and further reduced after wipe-out.

16. Multifocal ERG (mfERG) / full-field ERG (ffERG). Helps separate retinal causes (abnormal ERG) from pure optic nerve causes (often relatively preserved ERG).

E) Imaging & perimetry

17. Standard automated perimetry (SAP) 10-2 (± 24-2). Best tool to measure the central 10° and detect split fixation; documents the sudden central loss and follows change. EyeWiki

18. Optical coherence tomography (OCT) macula and RNFL/GCC. Shows macular edema, hypotony maculopathy, choroidal folds, and measures nerve fiber layers; helps exclude mimics and quantify structural loss. EyeWiki

19. OCT-angiography (OCT-A) (if available). Non-invasive map of perfusion in the macula and optic nerve head; may show capillary drop-out in vascular explanations.

20. B-scan ultrasonography (± ultrasound biomicroscopy). Detects choroidal effusions or suprachoroidal hemorrhage when media is hazy or the fundus view is limited.

Non-pharmacological treatments (therapies & other measures)

These approaches either reduce the chance of wipe-out, treat visible causes of early vision loss after glaucoma surgery, or support vision function. They complement—not replace—medical/surgical care.

1. Pre-operative risk counseling & shared decision-making: explain the small but serious risk of severe post-op vision loss (including wipe-out), especially in advanced glaucoma with split fixation, so expectations are realistic and consent is informed. Purpose: align goals and reduce distress. Mechanism: informed choices reduce risky scenarios and improve follow-up. EyeWikiJAMA Network

2. Optimize systemic blood-pressure patterns: review night-time antihypertensives and treat nocturnal hypotension or sleep apnea; avoid peri-operative over-aggressive BP lowering that could impair optic nerve perfusion. Mechanism: preserves optic nerve blood flow during vulnerable hours. American Academy of Ophthalmology

3. Choose anesthesia to minimize pressure/flow swings: in very advanced glaucoma, some surgeons prefer topical/sub-Tenon’s over retrobulbar blocks to avoid transient optic nerve perfusion changes and IOP spikes. Mechanism: gentler hemodynamics, less risk of pressure spikes. (Expert practice-pattern rationale.) American Academy of Ophthalmology

4. Stage or tailor surgery (e.g., combine MIGS or controlled drainage): for end-stage eyes, consider less abrupt IOP lowering (dose-titrated mitomycin C, tighter flap sutures, staged release). Mechanism: avoids sudden perfusion shifts. American Academy of Ophthalmology

5. Tight early post-op monitoring (first 1–2 weeks): frequent checks for hypotony, choroidal effusions, macular changes, IOP spikes; early intervention prevents lasting damage. Mechanism: catch treatable causes early. Medscape

6. Head positioning & activity moderation: short-term head-up sleeping, avoid heavy lifting/Valsalva, and protective eye shield at night. Mechanism: steadier choroidal venous pressure, less effusion risk. PMC

7. Hydration and salt balance guidance: avoid dehydration or large evening salt loads that can destabilize BP and ocular perfusion. Mechanism: stabilize systemic perfusion to optic nerve (supportive). American Academy of Ophthalmology

8. Low-vision strategies (if vision drops): early low-vision rehab, contrast enhancement, task lighting, and eccentric viewing training to maximize remaining function. Mechanism: neuro-adaptation and accessibility.

9. Blue-light/contrast management for macular sensitivity: use tinted lenses, contrast-boosting settings; helpful if macular folds/edema present. Mechanism: improves signal-to-noise.

10. Glycemic and lipid control (if diabetes/dyslipidemia): tighter metabolic control supports retinal/optic nerve perfusion. Mechanism: vascular health support.

11. Stop smoking: reduces vasospasm and improves microvascular health. Mechanism: better oxygen delivery to optic nerve.

12. Stress-sleep hygiene: prioritize sleep quality (treat OSA), as nocturnal hypoxia/hypotension worsens risk. Mechanism: steadier nocturnal perfusion. American Academy of Ophthalmology

13. Gradual return to exercise (doctor-guided): light aerobic activity after clearance; avoid straining early. Mechanism: cardiovascular benefits without pressure spikes.

14. Close OCT & visual-field surveillance: use macular OCT and 10-2 fields for central damage tracking; flags emerging edema/splitting. Mechanism: detects treatable “pseudo–wipe-out” causes. EyeWiki

15. Suture management & bleb care: timely suture lysis/adjustment to avoid hypotony or high IOP; meticulous bleb hygiene. Mechanism: stabilizes IOP profile. American Academy of Ophthalmology

16. Protective eyewear: prevent trauma that could trigger choroidal hemorrhage or disrupt a fresh bleb. Mechanism: reduces secondary harm.

17. Medication reconciliation: review and pause aqueous suppressants if hypotony develops; avoid agents that worsen low pressure. Mechanism: restores healthy IOP. Medscape

18. Early optical correction: refraction update when macula stabilizes; treat induced astigmatism (e.g., from macular folds) as vision recovers. Mechanism: maximizes acuity.

19. Driving/workplace safety planning: adjust tasks until vision and depth perception are known. Mechanism: reduces injury risk.

20. Psychological support: sudden vision change is distressing—offer counseling and peer support. Mechanism: improves adherence and coping.

---

Drug treatments

Medications address treatable causes of early post-op vision loss (the “pseudo–wipe-out” group). Always prescribe by specialist oversight. Typical doses below are general clinical ranges—they’re not individualized medical advice.

1. Cycloplegics (e.g., atropine 1% ophthalmic, 1 drop BID–TID short-term)
   Purpose: reduce ciliary spasm, deepen AC, help choroidal effusions.
   Mechanism: relaxes ciliary body; can modestly raise IOP when hypotony is present.
   Side effects: light sensitivity, near-blur, dry mouth (systemic). Medscape

2. Topical corticosteroids (e.g., prednisolone acetate 1% QID then taper)
   Purpose: treat intraocular inflammation and CME contributors.
   Mechanism: anti-inflammatory; improves blood-retina barrier.
   Side effects: pressure rise, infection risk, delayed healing. Medscape

3. Topical NSAIDs (e.g., ketorolac 0.5% QID; nepafenac 0.1% TID)
   Purpose: aid cystoid macular edema control alongside steroids.
   Mechanism: COX inhibition reduces prostaglandin-mediated edema.
   Side effects: surface irritation, rare corneal issues. PMC

4. IOP-lowering agents for pressure spikes

• Beta-blockers (timolol 0.5% QD–BID)

• Alpha-agonists (brimonidine 0.2% TID)

• Topical CAIs (dorzolamide 2% TID)

• Oral acetazolamide (250–500 mg PO up to QID short-term)
  Purpose: control early IOP spikes that threaten fragile nerves.
  Mechanism: reduce aqueous production or increase outflow.
  Side effects: fatigue, dry mouth, paresthesias; CAIs: sulfa allergy issues, metabolic acidosis. Ajo

Important: If hypotony is present, stop/suspend aqueous suppressants to avoid keeping IOP too low. Medscape

5. Systemic corticosteroids (e.g., prednisone 0.5–1 mg/kg/day short course)
   Purpose: heavy choroidal effusions or marked inflammation threatening the macula.
   Mechanism: powerful anti-inflammatory; reduces exudation.
   Side effects: hyperglycemia, mood, infection risk—specialist supervision needed. Medscape

6. Topical hypertonic saline (5% drops/ointment)
   Purpose: reduce corneal edema contributing to blur after hypotony.
   Mechanism: osmotic fluid shift from cornea.
   Side effects: stinging.

7. Carbonic anhydrase inhibitor for CME (selected cases)
   Purpose: off-label acetazolamide can help CME by modifying RPE pump function.
   Mechanism: enhances fluid resorption across RPE.
   Side effects: as above; use selectively. PMC

8. Antibiotic prophylaxis (short-term per surgeon)
   Purpose: protect a fresh bleb to lower infection risk during healing.
   Mechanism: reduces bacterial load.
   Side effects: local irritation.

9. Hyperosmotics (e.g., IV mannitol pre-op or early post-op spikes)
   Purpose: quickly reduce dangerous IOP spikes in high-risk eyes.
   Mechanism: osmotic gradient shrinks vitreous volume.
   Side effects: fluid shifts, electrolyte issues—hospital setting. Ajo

10. IOP-raising agents for stubborn hypotony (special situations)
    Purpose: off-label phenylephrine or atropine may help modestly; primary fix is procedural, not drops.
    Mechanism: increases ciliary tone, reduces uveal outflow.
    Side effects: tachycardia, hypertension (systemic phenylephrine).

---

Dietary “molecular” supplements

These do not treat wipe-out directly. They target retinal/optic-nerve metabolic support or vascular health. Discuss with a clinician—some have medication interactions or limited evidence.

1. Omega-3 fatty acids (EPA/DHA 1–2 g/day) – anti-inflammatory, endothelial support; may aid microcirculation.

2. Lutein + Zeaxanthin (10 mg/2 mg daily) – macular pigment support and antioxidant effects.

3. Nicotinamide (Vitamin B3; 1–3 g/day in studies) – investigational neuro-energetic support for RGCs; monitor liver function/flush.

4. Citicoline (500–1000 mg/day oral) – neurotrophic support; small studies suggest visual pathway benefits in glaucoma.

5. Coenzyme Q10 (100–200 mg/day) – mitochondrial antioxidant; potential RGC protection.

6. Alpha-lipoic acid (300–600 mg/day) – antioxidant; vascular and neural support.

7. Magnesium (200–400 mg/day) – vasodilatory/anti-spasm; may help vascular dysregulation.

8. Resveratrol (100–250 mg/day) – antioxidant; endothelial benefits (limited clinical data).

9. Vitamin D (per labs, often 1000–2000 IU/day) – general neurovascular health; correct deficiency.

10. Ginkgo biloba extract (120–240 mg/day) – may improve microcirculation in normal-tension glaucoma; watch for bleeding risk and drug interactions.

(Evidence for supplements ranges from preliminary to moderate; they are adjunctive only.) (General vascular/optic-nerve support concepts; see macular/optic-nerve perfusion discussions.) American Academy of Ophthalmology

---

Therapies in the “hard immunity booster / regenerative / stem-cell”

There are no approved “immunity boosters,” stem-cell drugs, or proven neuro-regenerative medications that reverse wipe-out. The items below are investigational or supportive and should not be pursued outside regulated clinical trials.

1. Nicotinamide (Vitamin B3) + pyruvate combinations (research) – aims to re-energize retinal ganglion cells (RGCs) under stress. (Preclinical/early clinical glaucoma work.)

2. Citicoline (neurotrophic support) – small human studies suggest functional benefits in glaucoma pathways; not a cure.

3. Rho-kinase–pathway strategies – while netarsudil is approved for IOP, broader ROCK-modulation and neuroprotection remain investigational.

4. CNTF (ciliary neurotrophic factor) intraocular implants – studied for retinal diseases to support neurons; glaucoma/regeneration application is investigational.

5. Mesenchymal stem-cell–derived exosomes – experimental neuroprotective signaling; clinical safety/efficacy unproven in glaucoma.

6. Visual restoration neuro-rehabilitation – structured perceptual training may improve functional use of remaining vision; this is rehab, not biologic regeneration.

Bottom line: promising science, no established regenerative drug for wipe-out today. (Context from contemporary reviews of vision loss after surgery and neuroprotection discourse.) PMC

---

Procedures/surgeries

1. Anterior chamber (AC) reformation with viscoelastic
   Why: treats flat/shallow AC and hypotony that threaten the macula.
   What happens: surgeon injects a viscoelastic into the AC to restore depth and pressure. American Academy of Ophthalmology

2. Bleb revision or compression sutures
   Why: correct over-filtration hypotony or leaking bleb.
   What happens: tighten/reshape scleral flap or place sutures; sometimes autologous blood patch is used. American Academy of Ophthalmology

3. Drainage of choroidal effusions/hemorrhage
   Why: large effusions can distort the macula and crush vision; hemorrhage is an emergency.
   What happens: controlled sclerotomy to drain fluid/blood and re-form the eye. Medscape

4. Bleb needling or flap loosening (for pressure spikes)
   Why: if IOP is too high, the bleb may be “tight.”
   What happens: needling or laser suture lysis increases outflow—reducing damaging spikes in fragile nerves. Ajo

5. Cataract extraction (when lens opacification is the real cause)
   Why: in some series, lens changes were the main reason for early vision loss after trabeculectomy.
   What happens: standard phacoemulsification after the eye stabilizes. ResearchGate

---

Preventions

1. Identify high-risk eyes (advanced field loss, split fixation, central defects) before surgery. EyeWiki

2. Discuss wipe-out explicitly during consent; set close early follow-up. Lippincott Journals

3. Avoid extreme early hypotony: flap suturing strategy, cautious MMC dosing, bleb design. American Academy of Ophthalmology

4. Avoid large immediate pressure swings: staged IOP reduction where reasonable. Ajo

5. Optimize systemic BP and oxygenation, especially at night; address OSA. American Academy of Ophthalmology

6. Promptly treat choroidal effusions/CME if they appear. PMC

7. Early OCT macula + 10-2 fields to surveil the central area. EyeWiki

8. Tailor anesthesia to minimize sudden IOP/perfusion shifts in end-stage eyes. American Academy of Ophthalmology

9. Educate about warning symptoms (central blur, dark spot, distortion) and urgent access.

10. Medication reconciliation post-op (pause aqueous suppressants if hypotony). Medscape

---

When to see a doctor

• Urgent—same day: sudden central blur or “dark patch,” rapidly worsening vision, curtain-like shadow (possible choroidal issue), severe pain (possible hemorrhage/IOP crisis), bleb leak with tearfulness or discharge. Medscape

• Prompt—within 24–48 hours: new distortion/waviness, increasing light sensitivity, deep ache, or haloing that doesn’t settle—possible CME, effusion, or pressure problem. PMC

• Routine but soon: any noticeable drop in reading or face recognition after surgery. Early assessment prevents long-term harm.

---

What to eat” and “what to avoid

Eat more of:

1. Leafy greens & colorful vegetables – antioxidants for retinal health.

2. Fatty fish (2–3×/week) – omega-3s support endothelium and microcirculation.

3. Whole grains & legumes – steadier blood sugar supports vascular health.

4. Nuts & seeds – healthy fats and magnesium.

5. Citrus/berries – vitamin C and polyphenols.

Limit/avoid:

1. Smoking (strictly avoid) – vasoconstriction harms optic-nerve perfusion.
2. Heavy evening salt – can destabilize BP/fluids overnight.
3. Excess caffeine/energy drinks – transient IOP effects and BP variability.
4. Binge alcohol – BP swings/dehydration.
5. Ultra-processed, high-glycemic foods – vascular stress.

(Diet supports overall ocular perfusion; it does not “cure” post-op vision loss.) American Academy of Ophthalmology

---

Frequently Asked Questions

1) Is wipe-out the same as any vision loss after trabeculectomy?
No. Many post-op causes are identifiable and treatable (hypotony maculopathy, effusions, CME, pressure spikes). Wipe-out is sudden central loss with no clear cause after careful work-up. EyeWiki

2) How common is it?
Uncommon and debated. Studies report 0%–~7% depending on definitions and methods. Glaucoma TodayAmerican Academy of Ophthalmology

3) Who is at highest risk?
People with very advanced glaucoma, split fixation/central field damage, and older age appear at higher risk. JAMA NetworkAAO Journal

4) When does it happen?
Typically immediately or within days after surgery. EyeWiki

5) Can it get better later?
If the vision loss is from a treatable cause (pseudo–wipe-out), recovery is possible once that problem is fixed. True wipe-out is usually permanent. PMC

6) Does mitomycin-C increase the risk?
Some older series of trabeculectomy + MMC reported rare “snuff-out” cases; overall, definitive causation is unclear and careful dosing/technique is emphasized. JAMA Network

7) Can pressure going too low cause it?
Hypotony can cause macular changes that severely lower vision; that’s typically an explained cause, not “true” wipe-out, but it must be treated fast. PMCMedscape

8) What tests will my doctor do if my vision drops?
Dilated exam, IOP check, OCT of the macula/nerve, 10-2 visual field, and sometimes B-scan or additional imaging to look for effusions or hemorrhage. EyeWiki

9) Can OCT really help?
Yes—OCT can spot hypotony-related macular folds or CME that explain vision loss and guide treatment. PMC

10) Is anesthesia a factor?
It might be—some surgeons minimize techniques that could cause transient perfusion/IOP swings in end-stage eyes. American Academy of Ophthalmology

11) Are there eye drops to reverse wipe-out?
No drop reverses true wipe-out. Drops help treat identifiable causes (IOP spikes, inflammation, CME). Ajo

12) Are “neuroprotective” vitamins or stem cells proven to restore vision?
Not at this time. Supplements and experimental therapies are adjuncts only; no approved regenerative drug for wipe-out exists. PMC

13) Can cataract be the reason my vision fell after surgery?
Yes—some studies found lens changes were the main cause of early acuity drop after trabeculectomy; if so, cataract surgery can help. ResearchGate

14) What if my IOP is perfect but vision is worse?
Your doctor will look for non-pressure causes (macular edema, effusions, ischemia, lens). If none explain it, they may consider wipe-out as a diagnosis of exclusion. PMC

15) Bottom line to prevent trouble?
Pick an experienced surgeon, share your medical history, attend all early follow-ups, and report any vision change immediately. Careful technique and rapid treatment of complications offer the best protection.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 30, 2025.